Clinical Scorecard: Efficacy of Osteoporosis Treatment Following Successful Parathyroidectomy for Primary Hyperparathyroidism: Results from a Randomized, Double-Blind, Placebo-Controlled Study

At a Glance

Key Highlights

• pHPT increases fracture risk up to fivefold, especially vertebral fractures, due to low BMD.
• Parathyroidectomy (PTX) improves BMD modestly but fracture risk remains elevated for up to 10 years post-surgery.
• Strontium ranelate (SR), an anti-osteoporotic medication stimulating bone formation and reducing resorption, was studied post-PTX to enhance BMD recovery.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of pHPT confirmed biochemically with elevated calcium and PTH levels.
• Osteopenia and osteoporosis defined by WHO T-score criteria (osteopenia: T-score ≤ -1 and > -2.5; osteoporosis: T-score ≤ -2.5).
• Preoperative exclusion of conditions affecting bone metabolism or contraindicating treatment (e.g., thromboembolism, renal impairment, recent bisphosphonate use).

Management

• Parathyroidectomy is the only causal treatment for pHPT and recommended even in patients without severe symptoms but with reduced BMD.
• Postoperative supplementation with calcium (1000 mg daily) and vitamin D (800 IU daily).
• Randomized administration of strontium ranelate 2 g daily or placebo starting 4 weeks post-PTX for 1 year to improve BMD.

Monitoring & Follow-up

• Bone mineral density measured by dual-energy X-ray absorptiometry (DXA) at lumbar spine, femoral neck, and radius sites.
• Biochemical markers of bone metabolism including sclerostin (SOST) and Dickkopf-1 (DKK-1) to assess Wnt signaling pathway activity.
• Electrocardiograms and cardiovascular risk assessment per European Medicines Agency guidelines for patients on strontium ranelate.

Risks

• Potential elevated risk of thromboembolism and cardiovascular events with strontium ranelate use.
• Exclusion of patients with ischemic cardiac disease, peripheral arterial obstructive disease, cerebrovascular disease, and uncontrolled hypertension.
• Persistent or recurrent pHPT and malignancies excluded postoperatively to avoid confounding treatment effects.

Patient & Prescribing Data

Postmenopausal women and men with pHPT and preoperative osteopenia or osteoporosis undergoing parathyroidectomy.

Strontium ranelate administered post-PTX aims to stimulate bone formation and inhibit resorption, potentially accelerating BMD recovery and reducing fracture risk.

Clinical Best Practices

• Screen and confirm pHPT diagnosis with biochemical testing and assess BMD preoperatively.
• Perform parathyroidectomy according to established surgical guidelines for pHPT.
• Initiate calcium and vitamin D supplementation immediately post-surgery.
• Consider anti-osteoporotic therapy with anabolic and antiresorptive properties, such as strontium ranelate, in patients with low BMD after PTX.
• Monitor BMD and biochemical markers regularly to evaluate treatment response and bone metabolism.
• Screen for cardiovascular risk factors prior to initiating strontium ranelate and monitor during treatment.

References

• Primary hyperparathyroidism and bone metabolism overview
• WHO criteria for osteoporosis diagnosis
• European guidelines for pHPT management
• Strontium ranelate effects on fracture risk
• Wnt signaling pathway and bone metabolism